Compounded Semaglutide Is Ending: What Patients Need to Know
Compounded semaglutide is being phased out following the FDA shortage resolution. Here is what is changing, who it affects, and how to transition to branded medication.
For much of 2023 and 2024, compounded semaglutide was how millions of people in the United States accessed GLP-1 medication. Ozempic and Wegovy were backordered, costs were high, and compounding pharmacies stepped in to fill the gap legally - because FDA rules allow compounding when a drug is on the shortage list.
That situation has changed significantly. Here is what happened and what patients should do now.
Why compounding was legal - and why it is ending
Under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, licensed compounding pharmacies can legally make copies of brand-name drugs when those drugs appear on the FDA's Drug Shortage List.
Semaglutide (Ozempic and Wegovy) appeared on that list in 2022 and 2023 due to unprecedented demand. This opened the door for compounding pharmacies - and telehealth platforms like Hims & Hers, Ro, and others - to sell compounded semaglutide legally and at lower prices.
In early 2025, the FDA determined that the shortage had resolved and removed semaglutide from the shortage list. This removed the legal basis for most compounding operations. The FDA then issued guidance giving compounders a phase-out period to wind down production.
As of March 2026, Hims & Hers - one of the largest sellers of compounded semaglutide - announced it would stop advertising and offering compounded GLP-1 medications following an agreement with Novo Nordisk. Customers are being transitioned to branded Ozempic and Wegovy.
What this means for patients currently on compounded semaglutide
If you are currently taking compounded semaglutide from any source:
- Your supply may be cut off or reduced without much notice, depending on your pharmacy or telehealth provider
- Switching to branded requires a prescription - either from your existing provider or a new one
- The dose may differ - compounded products were sometimes made at different concentrations; your doctor will recalibrate your dose on branded medication
- Do not stop abruptly without a plan - if you have been on GLP-1 medication for weight management or diabetes, stopping suddenly will bring back appetite and may affect blood sugar
Your options for branded semaglutide
Access to branded semaglutide has improved significantly compared to 2023.
NovoCare Pharmacy (Novo Nordisk direct)
Novo Nordisk's own pharmacy offers Wegovy at $499/month self-pay for uninsured or underinsured patients. Visit novocare.com for current pricing.
Telehealth platforms (post-agreement)
Following the March 2026 agreement, Hims & Hers now offers branded Ozempic and Wegovy at the same Novo Nordisk self-pay prices. Other telehealth providers including Ro, Found, and Calibrate also offer branded prescriptions.
Insurance
Many insurance plans now cover Wegovy for obesity, especially following the SELECT trial demonstrating cardiovascular benefits. If your plan has changed or you have not checked recently, it is worth requesting a prior authorisation.
Price reduction in 2027
Novo Nordisk announced on February 24, 2026 that Wegovy's list price will drop to $675 per month effective January 1, 2027 - a reduction of approximately 50%. Ozempic will drop to the same $675 (a 35% reduction).
Branded vs compounded: what actually changed?
| Branded Ozempic/Wegovy | Compounded Semaglutide | |
|---|---|---|
| FDA approved | ✅ Yes | ❌ No |
| Manufacturing quality control | ✅ Verified | Varies by pharmacy |
| Consistent dosing | ✅ Yes | Not guaranteed |
| Available at pharmacies | ✅ 70,000+ nationwide | Telehealth / mail only |
| Covered by insurance | ✅ Potentially | ❌ No |
The core concern with compounded semaglutide was never that the concept was wrong - it was that quality control was inconsistent. Some compounders used sodium salt forms of semaglutide rather than the acetate form in branded products, and some products had incorrect concentrations.
Tracking after you switch
Switching from compounded to branded semaglutide is a medication change that affects your routine. The titration schedule may restart from a lower dose, your injection format will change (to the Novo Nordisk pen), and your side effect profile may shift during the adjustment period.
Keeping a consistent log through the transition - dose, side effects, appetite, weight - is the most practical way to track whether the switch is going smoothly.
Final takeaway
Compounded semaglutide is being phased out following the resolution of the FDA shortage. If you are currently on compounded medication, now is the time to talk to your doctor about transitioning to branded Ozempic, Wegovy, or Wegovy pill. Access is better and prices are lower than they were in 2023, and a major price reduction is coming in January 2027.
Consult your healthcare provider before making any changes to your medication.
Sources
- FDA Drug Shortage List resolution for semaglutide (2025)
- FDA guidance on 503A/503B compounding and shortage criteria
- Novo Nordisk / Hims & Hers partnership announcement, March 9, 2026
- Novo Nordisk list price reduction announcement, February 24, 2026
- Wegovy FDA approval history: drugs.com/history/wegovy.html
FAQ
Why is compounded semaglutide being discontinued?
Compounded semaglutide was legal under FDA rules because Ozempic and Wegovy were on the official drug shortage list. Once the FDA removed semaglutide from the shortage list in early 2025, the legal basis for compounding largely ended. Pharmacies that continue to compound semaglutide after the deadline are operating outside FDA regulations.
Is compounded semaglutide safe?
Compounded semaglutide is not FDA-approved. Its quality, purity, and concentration are not independently verified the way branded products are. The FDA has warned about adverse events linked to compounded semaglutide products, including some involving incorrect dosing.
What should I do if I am currently on compounded semaglutide?
Talk to your prescribing doctor or telehealth provider. They can transition you to branded Ozempic, Wegovy, or in some cases Rybelsus (oral). Several access programmes now make branded semaglutide more affordable than it was a year ago.
Is branded Ozempic or Wegovy now cheaper?
Access has improved significantly. Novo Nordisk's NovoCare Pharmacy offers self-pay pricing, and major telehealth platforms including Hims & Hers now offer branded semaglutide at competitive prices following a March 2026 agreement. Novo Nordisk also announced a list price reduction to $675/month effective January 2027.